Brokers Offer Predictions for BLFS Q1 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for BioLife Solutions in a note issued to investors on Monday, November 18th. HC Wainwright analyst Y. Chen forecasts that the medical equipment provider will earn ($0.10) per share for the quarter. HC Wainwright has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for BioLife Solutions' current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for BioLife Solutions' Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.41) EPS.

A number of other brokerages have also weighed in on BLFS. Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Northland Securities lifted their price target on BioLife Solutions from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. Finally, TD Cowen lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $27.50.

BioLife Solutions Stock Performance

Shares of NASDAQ BLFS traded up $1.89 during midday trading on Wednesday, reaching $24.33. 518,710 shares of the stock were exchanged, compared to its average volume of 383,313. The firm has a 50-day simple moving average of $23.92 and a two-hundred day simple moving average of $22.87. BioLife Solutions has a twelve month low of $11.91 and a twelve month high of $28.88. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -21.17 and a beta of 1.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Stifel Financial Corp boosted its stake in BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after buying an additional 670 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in BioLife Solutions by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider's stock worth $392,000 after buying an additional 700 shares during the last quarter. GAMMA Investing LLC boosted its stake in BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock worth $83,000 after buying an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in BioLife Solutions by 5.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider's stock worth $296,000 after buying an additional 753 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in shares of BioLife Solutions by 1.4% in the 1st quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider's stock valued at $1,117,000 after purchasing an additional 839 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

Insider Buying and Selling at BioLife Solutions

In related news, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares of the company's stock, valued at $2,883,097.76. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Aby J. Mathew sold 17,604 shares of BioLife Solutions stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $20.05, for a total value of $352,960.20. Following the sale, the executive vice president now owns 284,442 shares of the company's stock, valued at approximately $5,703,062.10. This represents a 5.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,644 shares of company stock worth $1,527,503 over the last three months. Insiders own 2.20% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.